Offline mode

Cardiolipin IgG / IgM ELISA

Catalog no.RE70521
Regulatory Status
EU: CE
Kit size
12 x 8
Method
ELISA
Incubation time
3 x 30 min
Standard range
0 - 300 GPL/mL, 0 - 300 MPL/mL, cut-off 15 GPL/mL, cut-off 15 MPL/mL
Specimen / Volumes
10 µL serum
Substrate / isotope
TMB 450 nm

Intended Use

Cardiolipin-Ab IgG/IgM ELISA is a solid phase enzyme immunoassay employing highly purified cardiolipin plus native human ß2-glycoprotein I for the quantitative and qualitative detection of IgG and /or IgM antibodies against cardiolipin in human serum. Anti-cardiolipin antibodies mainly recognize specific epitopes on a complex composed of cardiolipin and ß2-glycoprotein I which are only expressed when ß2-glycoprotein I interacts with cardiolipin.

The assay is an aid in the diagnosis and risk estimation of thrombosis in patients with systemic lupus erythematosus (SLE).

Clinical Application and Principle of the Assay

Antibodies against cardiolipin belong to the group of anti-phospholipid antibodies specific for negatively charged phospholipids, components of biological membranes. Cardiolipin is an acidic phospholipid derived from glycerol and was namend because of its isolation from bovine heart in 1941. Anti-phospholipid antibodies are frequently found in sera of patients with systemic lupus erythematosus (SLE) and related diseases. The prevalence of anticardiolipin antibodies in SLE is 24-50 %.

The occurrence of anti-cardiolipin antibodies in patients with SLE and related diseases is typical for a secondary anti phospholipid syndrome (APS). In contrast, anti-cardiolipin antibodies in patients with no other autoimmune diseases characterize the primary antiphospholipid syndrome (APS). Many studies have shown a correlation between these autoantibodies and an enhanced incidence of thrombosis, thrombocytopenia and habitual abortions (as a consequence of placental infarct). The exact mechanism by which pathogenic anti-phospholipid antibodies induce thrombosis is not yet revealed fully.

Principle of the test

Serum samples diluted 1:101 are incubated in the microplates coated with the specific antigen. Patient´s antibodies, if present in the specimen, bind to the antigen. The unbound fraction is washed off in the following step. Afterwards anti-human immunoglobulins conjugated to horseradish peroxidase (conjugate) are incubated and react with the antigen-antibody complex of the samples in the microplates. Unbound conjugate is washed off in the following step. Addition of TMB-substrate generates an enzymatic colorimetric (blue) reaction, which is stopped by diluted acid (color changes to yellow). The intensity of color formation from the chromogen is a function of the amount of conjugate bound to the antigen-antibody complex and this is proportional to the initial concentration of the respective antibodies in the patient sample.

For concrete data please consult the Instruction for Use in the download box on the top right side.

  • Asherton, R.A., Harris, E.N. (1986). Anticardiolipin antibodies - Clinical associations. Post. grad. Med. J. 62, 1081-1087.
  • Boey, M.L., Colaco, C.B., Gharavi, A.E., et al. (1983). Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br. Med. J. 287, 1021-1023.
  • Gastineau, D.A., Kazmier, F.J., Nichols, W.L., Bowie, E.J. (1985). Lupus anticoagulant: analysis of the clinical and laboratory features of 219 cases. Am. J. Hematol. 19, 265-267.
  • Harris, E.N., Gharavi, A.E., Boey, M.L., et al. (1983). Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet Nov 26, 1211-1214
  • Wöhrle R, Matthias T, von Landenberg P, Oppermann M, Helmke K, Förger F (2000). Clinical relevance of antibodies against different phospholipids. Journal of Autoimmunity 15, A60.
  • Lothar Thomas: Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik., 8. Auflage, TH Books
  • CLSI Guideline GP44-A4: Procedures for the Handling and Processing of Blood Specimens for Common Laboratory Tests

Our Product Families

Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.

And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.

All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use. 

All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).

Image on background

This is who we are.

As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.

Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.

Happy to help.

At Tecan, we are driven to improve people’s lives and health.